Abbott and Novo Nordisk have allied to improve adhereics and monitoring of treatments for people with diabetes.Companies have presented two technologies integrated into the same 'app'.
In this way, the Abbott glucose monitoring system and the 'intelligent' insulin pen of Novo Nordisk send their data to a record that automatically allows the patient, that the patient can have a monitoring of his insulin administrationsimple.
Juan Francisco Perán, president of the Spanish Diabetes Federation (Fede), explained that this 'duo' of devices will cover a need that is not covered right now for diabetes patients.
"It will allow to self -manage the disease to each patient and will also improve management for their relatives," he explained.In addition, he stressed that the devices, thanks to their format, are suitable for all ages.
Javier Ampudia, a specialist in endocrinology and nutrition at the University Hospital of Valencia, explained that, in diabetes patients, glycemic control "is very important, since bad control is associated with greater chronic complications."
In addition, he has valued the role of Spain in glycemic control and has assured that the situation of the country "is better than in the United Kingdom or Germany, for example."
"We have improved the care of patients, the quality of insulins and the administration of these. We have good drugs, a national health system (SNS) and technological advances," he summarized.
innovation in diabetes
Focused on the operation of the two devices, José María Barranco, director of access to the market and sales of Abbott in Spain, explained that his company is responsible for the sensor.
"It is very simple to use, it lasts 14 days, and the data to the 'app' goes directly; it replaces the puncture on the finger," he explained.Thus, he commented that the sensor is integrated with the Novo Nordisk device and achieves a result "that 10 years ago was imposing and now puts a grain of sand in the improvement of expectations."
"I don't know if we will reach the cure of diabetes, but hopefully improve the control and quality of life of patients so that they do not feel they have diabetes."
"The goal is to make patients feel that they have diabetes"
For his part, Francisco Pajuelo, medical director of Novo Nordisk, explained the operation of his 'smart pen', which allows an easy administration of insulin.He commented that around 5000 people in Spain already have the device, which is funded by the SNS and that the operation of each device is secured five years.
"This collaboration with Abbott makes us put the patient in the center and in the long term it will help us improve complications; we are addressing the leg that remained with respect to when the pharmacological treatment is managed."
"It gives peace of mind to the patient, to the relatives and gives a complete vision to the health personnel so that the therapeutic determination that the most helps the patient can make," he concluded.